Method
Patients 41 patients with classical or definite rheumatoid arthritis (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959) ( Table I ) were found to be comparable for age, sex ratio, disease duration, presence of nodules and erosions, functional status, pain, morning stiffness, number of inflamed joints, ring size, and articular index (Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieveson, and Buchanan, 1968) . The initial grip strength was slightly less in the benorylate group. Patients were excluded if they had received steroids, gold, or anti-malarial drugs within the previous year, or had a definite history of aspirin intolerance.
Dosage
The drugs were presented as identical tablets and the patients were treated according to a predetermined random code. The daily dose of aspirin was 4g. and of benorylate 6g. The higher dosage of benorylate as compared with aspirin was chosen because absorption studies had previously shown that a dosage of 6g. of benorylate was approximately equivalent to administering a combined dosage of 3g. aspirin and 3g paracetamol (Robertson, 1971) . No other analgesics or anti-inflammatory drugs were permitted and physiotherapy was withheld for the duration ofthe trial. The ferric chloride test was performed at each attendance to check that the drugs were being taken. Assessment A preliminary assessment was made and the patient was given inert placebo tablets identical in appearance with the active drugs. Initially the placebo was given for 7 days, but because of the frequency of distressing relapses of joint pains this was reduced to the 48-hr period before the second assessment.
After the initial visit further assessments were made after 1 week, when the patient was started on either aspirin or benorylate, 5 weeks, 9 weeks, and at the end of the trial at 13 weeks. The clinical parameters recorded at each attendance are listed in Table I The index used was modified from the method of scoring on a four-point scale (0-1-2-3) the pain on palpating the joints, as described by Ritchie and others (1968 Both drugs produced an equal reduction in the overall pain level at the end of the study (P < 0 05). At the monthly assessments the benorylate group showed a progressive improvement in the total number of inflamed joints and in the articular index; after 3 months this improvement was significantly greater than that in the aspirin group. Improvement in grip strength and in the duration of morning stiffness occurred in both groups, but, because of the large standard error, differences between the drugs did not attain statistical significance. Throughout the study there were no significant changes in functional status or digital ring size in either group.
LABORATORY ANALYSES
Haematology Throughout the period of the trial there were no consistent changes in the measurements of erythrocyte sedimentation rate, haemoglobin, white cell, and platelet counts. Biochemistry The serum enzyme investigations (total and heat-labile LDH and aoHBDH) were performed as an indication of tissue damage (particularly hepatic tissue) or of in vivo haemolysis. They showed no regular pattern ofchange during the trial. The total LDH activities were raised in six patients from each group before participating in the trial, probably because of the rheumatoid arthritis itself or previous treatment. In all but one of these (a patient in the benorylate group), the levels returned to normal during the trial, although in some subjects there were temporary increases in total LDH activity. aoHBDH usually paralleled total LDH. Heat-labile LDH remained within normal limits in most patients, but increased after 4 weeks of treatment in five patients in the aspirin group.
One patient in the benorylate group had a raised heat-labile LDH, the total LDH and xHBDH being normal.
In (Table III) There were fewer spontaneous complaints in the benorylate group than in the aspirin group. There was more indigestion in the aspirin group.
Discussion
The results of the present study have shown that benorylate is an effective analgesic for the treatment of active rheumatoid arthritis. A significant antiinflammatory effect, as measured by a reduction in the erythrocytic sedimentation rate after 4 weeks has been demonstrated by Haslock, Nicholson, and Wright (1971) and Franke and Manz (1972) . Although we used the same daily dose of benorylate (6 g.), the present results have not confirmed their findings, but this may be due to the longer duration of the current study, as Franke and Manz (1972) found that the mean erythrocytic sedimentation rate had started to increase again after the fourth week. Hart and Huskisson (1972) suggested that a reduction in the circumference of the proximal interphalangeal joints was also a good assessment of anti-inflamma- Boardman and Hart (1967) were able to demonstrate a measureable anti-inflammatory response with aspirin, but this dose is often too high to be tolerated by outpatients for long periods of time. For this reason we used a daily dose of 4 g. aspirin, which is more commonly used in practice, and compared this with benorylate 6 g. a day, a dose which had been shown by other workers to be effective in rheumatoid arthritis. For ease of administration benorylate is now usually prescribed as a suspension. This preparation of the drug was not available when the present study was started, but Robertson, Glynn, and Watson (1972) have found no difference in the plasma salicylate levels when comparable amounts of the drug are given as tablets or as a suspension.
At the dose of 6 g., benorylate was well tolerated by the patients and gave rise to fewer side-effects than aspirin. This was most clearly seen with those sideeffects relating to the gastro-intestinal tractindigestion and nausea-which is in keeping with the findings of other authors. Cardoe (1970) and Franke and Manz (1972) found that faecal occult bleeding did not occur with benorylate therapy and a recent study by Cuddigan (1971) 
